Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
67.6 EUR | 0.00% | +0.22% | +93.70% |
Business Summary
Number of employees: 464
Sales per Business
EUR in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Innovative Cancer Medicines
100.0
%
| 278 | 100.0 % | 238 | 100.0 % | -14.37% |
Sales per region
EUR in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
88.8
%
| 0 | 0.0 % | 211 | 88.8 % | - |
Europe (excluding Germany)
11.2
%
| - | - | 27 | 11.2 % | - |
Asia
0.0
%
| - | - | 0 | 0.0 % | - |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Luisa Ciccarelli
CTO | Chief Tech/Sci/R&D Officer | - | 31/07/21 |
Tim Demuth
CTO | Chief Tech/Sci/R&D Officer | 50 | 30/09/22 |
Julia Neugebauer
IRC | Investor Relations Contact | - | 31/08/06 |
Daniel Palmacci
PRN | Corporate Officer/Principal | - | 30/06/20 |
Ann Merchant
PRN | Corporate Officer/Principal | 59 | 31/12/17 |
Ralf Ostendorp
PRN | Corporate Officer/Principal | - | 31/12/98 |
Corporate Officer/Principal | - | 30/04/94 | |
Klaus de Wall
AUD | Comptroller/Controller/Auditor | - | 31/05/05 |
Corporate Officer/Principal | - | 31/12/97 | |
Human Resources Officer | 54 | 29/05/12 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Sharon Curran
BRD | Director/Board Member | 56 | 21/05/19 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 37,716,423 | 2,130,820 ( 5.650 %) | 53,685 ( 0.1423 %) | 5.650 % |
Company contact information
Sector
Sales per region
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+16.59% | 45.51B | |
-9.89% | 38.52B | |
+38.08% | 38.13B | |
+27.12% | 30.74B | |
-8.64% | 26.03B | |
+11.81% | 25.92B | |
+45.08% | 14.13B | |
+32.85% | 12.73B | |
-7.19% | 11.29B |
- Stock Market
- Equities
- MOR Stock
- MOR Stock
- Company MorphoSys AG